Insurers pushing back against “me too” drugs

  • According to Reuters, a small little-known group of experts who advise U.S. health insurers on new drugs says that none of the three new migraine drugs offers a clear benefit over drugs already on the market, suggesting that they could consider them for optional coverage (which would limit their use).
  • Insurers have also signaled that a lot of the new immunotherapy cancer drugs may also face significant hurdles unless they show a clear benefit of drugs lredy on the market.
Continue reading